India Glycols Limited (INDIAGLYCO) shares insights from its investor presentation on Ennature Biopharma's growth strategy and market expansion.
India Glycols Limited (INDIAGLYCO) Q1FY27 results show double-digit growth in revenue, EBITDA, and PAT.
India Glycols Limited (NSE: INDIAGLYCO) stock moves down 5% intraday, showing pressure after breakout. Price at ₹1084.0.
India Glycols Limited (NSE: INDIAGLYCO) stock cleared its 6M resistance trendline, moving up 5% intraday to ₹1165.7.
India Glycols Limited (INDIAGLYCO) reports strong financial performance for Q4 & FY26, with revenue growth and improved margins.